Site of intravitreal injection and pain score Site of intravitreal injection pain
Conditions
Interventions
Superonasal quadrant intrvitreal bevcizumab injection,Superotemporal quadrant intrvitreal bevcizumab injection,Inferonasal quadrant intrvitreal bevcizumab injection,Inferotemporal quadrant intrvitreal
Superonasal quadrant injection,Superotemporal quadrant injection,Inferonasal quadrant injection,Inferotemporal quadrant injection
Sponsors
Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: Age > or = 20 years Diagnosed with neovascular (wet-type) age-related macular degeneration or diabetic macular edema or central retinal vein occlusion Confirmed with optical coherence tomography (OCT) or fundus fluorescein angiography (FFA) or both Need for intravitreal bevacizumab injection as the treatment for the first time in out-patient department or retina clinic, Department of Ophthalmology, KCMH
Exclusion criteria
Exclusion criteria: Patient with any of the following conditions: History of intravitreal injection Contraindicated in intravitreal injection Abnormality or scar on sclera, episclera or conjunctiva Ophthalmic disease requiring ophthalmic drop other than lubrication Intraocular pressure > or = 22 mmHg History of scleritis or episcleritis History of cranial nerve V abnormality History of intraocular surgery History of neovascular glaucoma Limitation of extraocular muscle interfering the injection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pain score at the end of intervention visual analog scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety; Adverse events 0, 2, 4, 8, 12, 24, 36, 48 hrs Safety monitoring, vital sign,Safety; Adverse events check-out each period (48 hrs) PT, aPTT | — |
Contacts
Public ContactChuthamas Ongprakobkul
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed